RBC Capital lowered the firm’s price target on Tandem Diabetes (TNDM) to $55 from $65 but keeps an Outperform rating on the shares. The company delivered a modest Q4 revenue beat but called out seasonally weaker trends toward quarter-end and issued 2025 guidance that is reflecting the seasonal trends into Q1 and expected sales force disruptions, the analyst tells investors in a research note. While the outlook is “underwhelming” however, Tandem still has catalysts in play this year, RBC adds.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Sell Rating for Tandem Diabetes Care Due to Revenue Shortfalls and High Valuation
- Tandem Diabetes price target lowered to $58 from $63 at Canaccord
- Tandem Diabetes Care: FDA Approval and Strategic Growth Opportunities Drive Buy Rating
- Tandem Diabetes Care Reports Record 2024 Sales Growth
- Tandem Diabetes Care: Strong International Sales and Promising 2025 Outlook Justify Buy Rating